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a  b  s  t  r  a  c  t
A  new  chemical  entity,  which  is  a chiral  indane  dimer,  PH46A,  has been  developed  by  our research  group.
As  a clinical  candidate.  PH46A  has  recently  completed  Phase  I  clinical  studies  in man.  Previously,  during
its  pre-clinical  development,  in  in  vivo  pre-clinical  studies  PH46A  showed  potent  anti-inflammatory
properties,  which  can  be targeted  at a range  of  diseases,  including  inflammatory  bowel  disease  (IBD).
To  support  the  pre-clinical  development  of  this  drug  candidate,  we  developed  a LC  MS/MS  method
for  determining  PH46  (the acid  form  of PH46A  salt)  in  both  dog  and  rat plasma  using  Compound  1  as
internal  standard  (IS).  Those  species  were  selected  for  safety  pharmacology  and toxicology,  as  well  as
pharmacokinetics  studies.
The method  was  validated  over the  range  10−10000  ng/mL  for both  matrices  and  the  linearity,  accuracy,
precision  and  specificity  over  this  range  were  demonstrated  to  be  acceptable.  No  significant  matrix  effects
or  carryover  were  observed  for  both  PH46  and  IS  and  recovery  was  consistent.  PH46  was  found  to  be
stable  in both  dog  and  rat  plasma  under  the  test  conditions,  such  as at room  temperature  for >24 h,
through  3 freeze/thaw  cycles,  and  at -20 ◦C for  >1  month.  PH46  and  IS in  dog  and  rat  plasma  extracts
were  also  found  to  be  stable  in  the autosampler  against  fresh  standard  extracts  on  re-injection  after
143.5  h and  243.5  h, respectively  at 4 ◦C. 10- and  100-fold  dilutions  with  control  matrix  were  found  not
to  affect  the  performance  of the  assay.  This  method  was successfully  applied  to  a pharmacokinetic  study
in the  dog.  With  the  exception  of  one  dog,  003  M, oral  administration  of PH46A  in gelatine  capsules  was
well  tolerated  at a dose  level of 100  mg/kg.  The  highest  Cmax was  observed  in  animal  003  M.  The  rapid
absorption  and  high  plasma  concentration  observed  for animal  003  M compared  to  the  data  for  animals
001  M  and  002  M may  account  for the  sickness  observed  in  this  animal;  however,  the  reasons  for  this
have  not  been  investigated.
©  2019  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Our research group have developed a series of indane dimers
and the biological activities of these molecules have been
investigated [1–6]. During the course of our work, a novel
indane scaffold was discovered which demonstrated potential
∗ Corresponding authors at: Drug Discovery Group, School of Pharmacy and Phar-
maceutical Sciences & Trinity Biomedical Sciences Institute, Trinity College, Dublin
2,  Ireland.
E-mail addresses: nfrnkish@tcd.ie (N. Frankish), hsheridn@tcd.ie (H. Sheridan).
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treatment of inflammatory conditions, in particular inflamma-
tory bowel disease (IBD) [7]. A lead, first-in-class molecule,
PH46A, 6-(methylamino)hexane-1,2,3,4,5-pentanol-4-(((1S,2S)-
1-hydroxy-2,3-dihydro-1H,1′H-[2,2-biinden]-2-yl) methyl)
benzoate [8,9] has been shown to have a biological effect in
two different well-established preclinical models of murine colitis:
the acute dextran sodium sulphate model and the chronic and
spontaneous Interleukin-10 (IL-10−/−) knock-out mouse model
[8]. This is indicative that PH46A has a therapeutic effect which
is independent of model specific aetiology. Based on the effects
in the animal models, PH46A is believed to be a potential new
https://doi.org/10.1016/j.jpba.2019.113011
0731-7085/© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Chemical structures of PH46A, PH46 and Compound 1 (IS).
treatment for patients with IBD and it has recently completed a
Phase I clinical trial study in healthy volunteers [10].
The in vitro comparative metabolism study of PH46A that we
recently published showed that PH46A metabolism in rat is most
similar to human, and all putative human metabolites are present
in rat, dog, mouse and cynomolgus monkey [11]. Rat and dog were
therefore selected as appropriate and useful species for use in
subsequent mandatory and pivotal GLP safety pharmacology and
toxicology studies in order to guide the clinical development of
PH46A. Further, at this time, studies in laboratory animals pro-
vide the best available basis for extrapolation to humans and are
required to support regulatory submissions. Acceptable models
which do not use live animals currently do not exist. The rat was
selected as the test model, since it is accepted by regulatory author-
ities as a rodent animal model for toxicity studies [12], high quality
animals are readily available, and a large amount of background
pathology data is available in this species. The dog was also selected
as the test model to meet regulatory requirements for testing in a
non-rodent species [12] and because of the availability of back-
ground data and the proven suitability in toxicology studies. As
part of the preclinical investigations, the characterisation of the
pharmacokinetics (PK) of PH46A in the rat and the dog were stud-
ied. To this end, this manuscript describes the development and
validation of sensitive and specific LC–MS analytical methods for
determining PH46 (the free acid form of PH46A salt) (Fig. 1) in
dog and rat plasma according to the Food and Drug Administra-
tion (FDA) [13] and the European Medicines Agency (EMA) [14]
guidelines. The method was subsequently applied to a PK study in
male Beagle dogs to quantitate levels of PH46 and evaluate its oral
bioavailability following oral administration of PH46A in capsule.
2. Materials and methods
2.1. Chemical and reagents
PH46A [purity 97.1 %; correction factor (purity and salt con-
tent): 0.6429] and Compound 1 as Internal Standard (IS, Fig. 1)
(purity 99.8 %) were obtained from Trino Therapeutics Ltd (Ireland).
Control rat (Sprague Dawley) and dog (Beagle) plasma and blood
were obtained from Charles River Laboratories (UK) using lithium
heparin as anticoagulant and stored at -20 ◦C when not in use
(all control plasma was mixed and centrifuged prior to use). HPLC
grade solvents and additives, including methanol (MeOH), acetoni-
trile (ACN), water, ammonia solution, acetic acid (AA), acetone,
dimethylsulphoxide (DMSO), chloroform and formic acid (FA),
were purchased commercially between VWR  (Ireland) and Sigma-
Aldrich (Ireland) and were used without further purification. Size
12 gelatine capsules (Torpac ‘Loc Ring Capsules’, USP grade) were
used to administer the dose for the pharmacokinetic study.
Table 1
Quality control data relating to PH46 in dog and rat plasma (results expressed as
ng/mL).
PH46 in dog plasma PH46 in rat plasma
25.0* 300* 8000* 25.0* 300* 8000*
Batch
7
24.4 319 8120 – – –
22.9 316 8730
Batch
12
22.9 298 9130 – – –
27.7 330 8550
Batch
17
24.1 337 8100 – – –
25.7 330 8610
Batch
18
– – – 24.2 306 7930
23.2 302 8480
Mean 24.6 322 8540 23.7 304 8210
Precision (%) 7.5 4.3 4.6 n/a n/a n/a
Accuracy (%) 98.5 107.2 106.8 94.8 101.3 102.6
* Nominal concentration of PH46. Precision: coefficient of variation of mean.
Accuracy: mean determined concentration/nominal concentration. n/a: not appli-
cable.
2.2. Animals and husbandry
All animal research work reported in this article have been car-
ried out in accordance with Directive 2010/63/EU and its Irish
transposition S.I No 543 of 2012. Ethical approval was  obtained
through Trinity College Dublin which complies with the Coun-
cil for International Organizations of Medical Sciences’ (CIOMS),
International Guiding Principles for Biomedical Research Involv-
ing Animals, and all laws, regulations and policies governing the
care and use of laboratory animals in the jurisdiction in which
the research is being conducted. Three male Beagle dogs (on-
study numbers: 001 M,  002 M and 003 M,  respectively) body weight
9.9–11.2 kg, were supplied by Charles River Laboratories (UK). Dur-
ing pre-trial and on-study periods, the animals were gang housed
in cages appropriate to the species. Prior to inclusion on this study,
animals were subject to a veterinary examination and the results
found to be satisfactory. All animals were weighed prior to each
dose administration and body weights recorded. Animals were
fasted overnight prior to dosing and offered standard laboratory
diet (PM1 Lab Diet 5007, Purina) for 2 h post-dose. Mains quality
tap water was  available ad libitum throughout the study.
2.3. Instrumentation and operation conditions
AB Sciex API 3000 LC/MS/MS System consisted of HPLC pump
(Series 200, Perkin Elmer), autosampler (HTS Pal, CTC Analytics),
column oven (Series 200, Perkin Elmer) and six-port switching
valve (Valco). Operations and data analysis were controlled by
data handling system (Analyst Version 1.4.2, AB Sciex) and Lab-
oratory Information Management System (Watson 7.0, Thermo
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Fisher Scientific). Halo C18 column (75 × 2.1 mm,  2.7 m,  HiChrom)
and PreFrit Filter guard column (0.5 m,  Anachem) was employed
at 60 ◦C with autosampler temperature at 4 ◦C. Mobile phase A:
MeOH:AA (100:0.2, v/v) and mobile phase B: water:AA (100:0.2,
v/v). The gradient was 40 % B (0 min), 20 % B (2.0 min), 20 % B
(4.0 min), 0 % B (4.5 min), 40 % B (4.7 min), 0 % B (4.9 min) and
40 % B (8.0 min). Flow rate was 0.3 mL/min with injection volume
of 10 L and run time of 8 min. The solvent mixtures for nee-
dle wash are MeOH/water/acetone/FA (40/40/20/1, v/v/v/v) and
MeOH/water/ammonia (50/50/1, v/v/v).
Mass spectrometric detection was performed using TurboIon-
Spray negative ionization mode. Standard API3000 nitrogen was
used for nebulizing and drying. Ion spray temperature was  550 ◦C
and ion spray voltage was −4500 V. The probe positions were 5 mm
(X) and 5 mm (Y). PH46 ion monitored was 381.10 → 135.10 (± 0.5)
dwell 150 msec and IS ion monitored was 379.10 → 134.14 (± 0.5)
dwell 150 msec.
2.4. Preparation of control matrix
The haemolysed plasma was prepared by overtaxing and freez-
ing an aliquot of the blood at −20 ◦C for a short period of time. This
was then thawed, centrifuged (3500 rpm, 4 ◦C & 10 min) and the
resultant plasma was transferred to a clean tube for use. All control
plasma was stored at −20 ◦C when not in use and was mixed and
centrifuged prior to use.
2.5. Preparation of calibration standards and quality control
samples
The primary stock solutions of PH46 and IS were prepared at
1000 g/mL in ACN/DMSO (50:50, v/v). The calibration standards
(CSs) were prepared by serially diluting the primary PH46 stock
solution in control matrix to give concentrations at 10, 20, 65, 250,
750, 2500, 9000 and 10000 ng/mL plasma. For each batch of sam-
ples, aliquots (50 L) of CSs were extracted in duplicate to give
a range of concentrations of PH46 within the linear range of the
assay and a fixed concentration of IS (300 ng/mL) prepared from
IS stock using MeOH/chloroform (50:50, v/v). Quality control (QC)
samples were prepared in control matrix from the primary PH46
stock solution in similar manner as CSs, to give QCs at 10 [Lower
Limit of Quantification (LLOQ)], 25 (low), 300 (medium) and 8000
(high) ng/mL plasma concentrations and aliquots (50 L) of QCs
were extracted for analysis. All the solutions were stored at −20 ◦C
and brought to room temperature before being analysed. A correc-
tion for batch specific purity was applied to all weighing, as well as
a correction for salt content (382.5/577.7; free acid/salt).
2.6. Sample extraction
Control plasma sample (Lithium Heparin anticoagulant) was
removed from the freezer and allowed to thaw at room temper-
ature. Control matrix was vortex mixed and centrifuged prior to
use. 50 L was added to each appropriate well of a clean round
bottomed 96 well plate for double blank (DB) (control matrix
only without PH46/IS) and single blank (SB)control matrix with
IS only) samples. CSs, QCs and test samples were removed from
the freezer and allowed to thaw at room temperature and vortex
mixed prior to aliquoting. 50 L was added to each appropriate
well of a clean round bottomed well plate. 50 L of IS [0.3 g/mL
in MeOH/chloroform (50:50, v/v)] was added to all samples except
for DBs, which received 50 L of MeOH/chloroform (50:50, v/v). A
further 500 L of MeOH/chloroform mixture was added to all sam-
ples and the plate was sealed and vortex mixed thoroughly prior
to centrifugation (3500 rpm, 5 min, 4 ◦C). The supernatant from all
samples was transferred into clean matrix tubes, dried under nitro- Ta
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gen at 60 ◦C and then reconstituted in 200 L of MeOH/water/AA
(50:50:0.2, v/v/v). The extracts were vortex-mixed and centrifuged
for 5 min  at 3500 rpm at 4 ◦C.
2.7. Validation procedures
The analytical method was  developed and validated for use on
the Tomtec robotic pipetter using 96 well plates and matrix tubes
in a 96 well format. Since the test sample PH46A was weighed and a
correction factor was use for the salt content, all peak area measure-
ment and determined concentrations reported were for PH46 acid.
Each batch of samples consisted of matrix DB, matrix SB, CSs, QC and
test sample extracts. One set of CSs was  injected at the start of the
run and one set at the end of the run. CSs were injected in concen-
tration order in each section of the run. QC samples were prepared
in control matrix at low, medium and high levels (n≥2 at each level).
Where n = 2, one low & one medium level QC samples were injected
at the start of the run after one set of CSs, and one low & one high
level QC samples were injected at the end of the run before the other
set of CSs. The remaining medium & high QCs were injected midway
through the run. Where n>2, the additional QCs were appropriately
distributed throughout the run. Solvent or extracted matrix DBs
were injected after high concentration extracts prior to injecting
a potentially low concentration extract in order to avoid the risk
of assay carryover. The target acceptance criteria for QCs was  that
the determined concentrations of at least 66 % of QCs in each batch
had to be within 100 ± 15 % of the nominal concentrations, includ-
ing at least one QC sample at each concentration had to meet this
criterion.
2.7.1. Stability of PH46 and IS in stored stock solutions
The effect of PH46 storing stock solutions in ACN/DMSO (50/50,
v/v) at 4 ◦C was investigated by comparison of peak area ratios of
freshly weighed stock solutions with stock solutions which had
been prepared 35 days previously. Both stock solutions were pre-
pared in the same way. The stock solutions were diluted to the
one upper limit of quantification (ULOQ) level with an appro-
priate diluent. The effect of storing solutions of IS (working and
stock solutions) in ACN/DMSO, (50/50, v/v) for the stocks and
MeOH/chloroform (50/50, v/v) for the working solution at 4 ◦C was
investigated by comparison of peak area ratios of freshly weighed
and diluted stock and working solutions with solutions which had
been prepared 35 (stocks) and 27 (working solutions) days previ-
ously. PH46 and IS were deemed to be stable if the mean detector
responses for the stored solutions were within 100 ± 10 % of the
mean detector responses of the freshly prepared solutions and the
precision is ≤10 %. The effect of storing stock solutions of PH46
in ACN/DMSO (50/50, v/v) at ambient room temperature was  also
studied by comparison of peak area ratios of an aliquot of the stock
solution stored at 4 ◦C with an aliquot of the same stock solution
stored at ambient room temperature for 24 h. Both solutions were
diluted to the ULOQ level with an appropriate diluent. PH46 was
expected to be stable at room temperature if the mean detector
responses for the solutions stored at room temperature were within
100 ± 10 % of the mean detector responses of the solutions stored
at ca 4 ◦C and the precision is ≤10 %.
2.7.2. Specificity and linearity
The assay specificity was determined by extraction and analysis
of six different sources of the matrix (different batches of matrix
were pooled from different animals). For each source, the sam-
ples were prepared, including one DB (control matrix only), one
SB (control matrix + IS), one LLOQ (IS only) and ULOQ (without IS).
If interfering peaks at the retention times (RTs) of PH46 or IS were
noted, these were deemed to be insignificant if the response at RT of
PH46 was ≤20 % of the response in LLOQ samples and if the response
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Fig. 2. Calibration curves for the determination of PH46 in dog (upper) and rat (lower) plasma.
Table 4
Effects of dilution of PH46 with dog and rat plasmas (results expressed as ng/mL).
Dilution of PH46 with dog plasma Dilution of PH46 with rat plasma
Dilution factor 10 100 10 100
Replicate n=6 n=6 n=6 n=6
Mean 68200 73500 74600 73700
Precision (%) 13.2 2.8 3.8 7.7
Accuracy (%) 85.3 91.9 93.3 92.1
at the RT of IS was ≤5 % of the IS response. The 16-point calibra-
tion curves over 10−10000 ng/mL were constructed by plotting the
peak area ratio of PH46:IS against the nominal matrix concentra-
tions of PH46 to determine the optimum regression parameters.
The matrix concentration of PH46 from each of CSs was calculated
from the corresponding curve. A DB sample and a SB sample were
also extracted and analysed, these were not included in the regres-
sion analysis. The acceptance criteria were that at least 75 % [a
minimum of 6 including at least one LLOQ and one ULOQ sample] of
the standards had to be back-calculated to be within 100 ± 15 % of
the nominal concentrations (100 ± 20 % at LLOQ). Confirmation of
linearity was performed at least on three separate occasions during
the validation.
2.7.3. Assay recovery and matrix effect
The matrix effects were determined by extracting replicate
(n = 6) samples of control matrix, from six individual sources
(one of these sources was  haemolysed plasma which matched
one of the non-haemolysed sources), and PH46 & IS solutions in
MeOH/water/AA (50:50:0.2, v/v/v) were spiked after extraction.
This resulted in replicate matrix effect samples (n = 3) at each of
the matrix equivalent PH46 concentrations of 25 and 8000 ng/mL
and IS concentration of 3000 ng/mL. Replicate (n = 3) non-extracted
QC samples were prepared in the same ratio as the extract sam-
ples. The matrix factor (MF) for PH46 and IS was determined in
each source of matrix by calculating the ratio of the mean response
of replicate samples spiked into matrix to the mean response of
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Fig. 3. Chromatograms of a dog plasma extract (left) containing PH46 (LLOQ, 10 ng/mL) & IS (3000 ng/mL) and a dog plasma extract (right) containing PH46 (ULOQ,
10000  ng/mL) & no IS.
Table 5
Stability tests of PH46 in dog & rat plasma (results expressed as ng/mL).
PH46 concentration in dog plasma PH46 concentration in rat plasma
25* 8000* 25* 8000*
a. Baseline 3 Cycles Baseline 3 Cycles Baseline 3 Cycles Baseline 3 Cycles
Replicate (n=6)
Mean 23.6 25.5 8260 8000 25.5 26.4 9130 8650
Precision (%) 2.9 3.6 4.4 4.0 3.8 3.1 5.5 9.1
Accuracy (%) 94.4 102.0 103.3 100.0 102.0 105.6 114.1 108.1
b.  Baseline 24 h Baseline 24 h Baseline 24 h Baseline 24 h
Replicate (n=6)
Mean 23.6 25.1 8260 7670 25.5 27.7 9130 91205.
Precision (%) 2.9 4.3 4.4 5.2 3.8 6.4 5.5 5.1
Accuracy (%) 94.4 100.4 103.3 95.9 102.0 110.8 114.1 114.0
c.  Baseline 31 days Baseline 31 days Baseline 30 days Baseline 30 days
Replicate (n=6)
Mean 23.6 25.1 8260 7900 25.5 25.4 9130 8420
Precision (%) 2.9 10.6 4.4 2.3 3.8 4.4 5.5 6.6
Accuracy (%) 94.4 100.4 103.3 98.8 102.0 101.6 114.1 105.3
d.  Baseline 143.5 h Baseline 143.5 h Baseline 243.5 h Baseline 243.5 h
Replicate (n=6)
Mean 25.4 25.1 8110 7630 26.1 26.1 8070 7410
Precision (%) 3.2 10.6 4.1 6.4 5.6 5.9 3.3 4.0
Accuracy (%) 101.6 100.4 101.4 95.4 104.4 104.4 100.9 92.6
e.  10* 25* 300* 8000* 10* 25* 300* 8000*
Replicate (n=6)
Mean 9.75 25.2 296 7500 8.71 25.4 318 8310
Precision (%) 11.6 11.9 7.2 13.7 11.0 7.9 1.8 5.3
Accuracy (%) 97.5 100.8 98.7 93.8 87.1 101.6 106 103.9
*Nominal concentration of PH46.
a. Freeze/thaw stability test; b. Ambient temperature stability test; c. Short term frozen matrix storage stability test; d. Autosampler stability (plasmas extract stored at 4 ◦C);
e.  Reinjection stability.
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Fig. 4. Chromatograms of a rat plasma extract (left) containing PH46 (LLOQ, 10 ng/mL) & IS (3000 ng/mL) and a rat plasma extract (right) containing PH46 (ULOQ, 10000 ng/mL)
&  no IS.
Table 6
Pharmacokinetic parameters of PH46 in male beagle dog plasma following PH46A oral capsule administration of 100 mg/kg.
Dog Cmax
(ng/mL)
Cmax/D
(ng/mL)/
(mg/kg)
Tmax (h) AUC(0-t)
(ng.h/mL)
AUC(0-t) /D
(ng.h/mL)/
(mg/kg)
AUC(0-inf)
(ng.h/mL)
AUC(0-inf)
/D
(ng.h/mL)/
(mg/kg)
T1/2 (h)
001M 7960 79.6 2.00 22200 222 22000 224 5.72
002M  21100 211 2.00 51100 511 51000 513 5.03
003M  34900 349 0.750 31700 317 n/r n/r n/r
n  3 3 3 3 3 2 2 2
Mean*  21300 213 2.00 35000 350 36900 369 5.38
SD  13500 135 - 14700 147 - - -
*Median for Tmax. n/r = Not reported, the coefficient of determination < 0.800.
the non-extracted samples. The IS-normalised MF  was calculated
by dividing PH46-MF by IS-MF from the same source. No matrix
effect in the samples was expected if the precision of the IS-
normalised MF  calculated from the six sources was ≤15 %. The assay
recovery was  determined by preparing, extracting and analysing
replicate (n = 3 at low, medium and high levels) matrix effect
samples from a single source of matrix (spiked after extraction).
Replicate (n = 3) extracted samples were prepared, extracted and
analysed as detailed in Section 6.10 at the same low, medium and
high concentrations as the matrix effect samples. The recoveries of
PH46 and IS were defined as the mean responses in the extracted
samples/the mean responses in the matrix effect samples.
2.7.4. Intra- and inter-batch assay accuracy and precision
The assay intra- and inter-batch accuracy and precision were
evaluated using replicate (n = 6) QC samples at 10 (LLOQ), 25
(low), 300 (medium) and 8000 (high) ng/mL. The intra- and inter
accuracy expressed as the mean percentage determined concen-
tration/nominal concentration, which was expected to be within
100 ± 15 % at each concentration level (100 ± 20 % at LLOQ level).
Intra- and inter-precision were determined by the coefficient of
variation of the mean determined concentration, which should be
≤15 % at each level (≤20 % at LLOQ level). The intra-batch assay
accuracy and precision were determined on three occasions and a
different batch of mobile phase was used on each occasion; three
batches at each level were used for inter-batch assays.
2.7.5. Assay carryover and matrix dilution
Carryover was  assessed by using replicate QCs (n = 2) at LLOQ &
ULOQ levels and additional replicate (n = 2) DBs. The sequence of
analysis was: 1 x ULOQ, 2 x DBs, 1 x LLOQ, 1 x ULOQ, 2 x solvent
samples (SSs) (MeOH/water/AA, 50:50:0.2, v/v/v) and 1 x LLOQ. No
assay carryover for PH46 can be concluded if the PH46 responses
in DB and SS were ≤20 % of the detector responses for PH46 in the
following LLOQ samples; no IS carry-over if the IS responses in DB
and SS were ≤5 % of the detector responses for IS in the preceding
ULOQ samples. Replicate (n = 6) QC samples were made by diluting
10- and 100-fold of a bulk stock (80000 ng/mL in control matrix).
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Fig. 5. The plasma concentration profiles (upper: liner plot & lower: semi-log plot) of PH46 in male beagle dog following oral capsule administration of 100 mg/kg PH46A.
Aliquots (50 L) (n = 6 of each dilution factor) were then extracted
(nominal concentrations of 8000 and 800 ng/mL). The determined
concentrations were corrected for the dilution factors. Matrix dilu-
tion was considered to be acceptable if the assay accuracy was
within 100 ± 15 % and the assay precision was ≤15 %.
2.7.6. Stability experiments
Six aliquots (50 L) of QCs at each low (25 ng/mL) and high
(8000 ng/mL) concentration levels were extracted and analysed
to confirm the suitability of the stability samples. Freeze/thaw
stability of PH46 in matrix was performed using replicate QCs sam-
ples (n = 6) at each concentration level receiving three freeze/thaw
cycles at −20 ◦C (initial freeze cycle at least 24 h, cycles 2 and 3 at
least 12 h and thaw cycle for an hour at room temperature).
Ambient room temperature stability of PH46 in matrix was
assessed on further QCs (n = 6) at each level after left at ambient
temperature for 24 h before extraction with fresh CSs and QCs.
Short term matrix frozen storage stability was achieved by
analysing replicate QCs (n = 6) at each concentration after one
month’s storage at −20 ◦C.
Low and high QC samples extracted and previously injected for
accuracy and precision batches (occasion two  for dog plasma and
occasion one for rat plasma) were re-injected for autosampler sta-
bility. The extracts had been stored at 4 ◦C for 143.5 h and 243.5 h
for dog and rat batches respectively.
Reinjection stability was assessed by using the occasion 1 accu-
racy and precision batches, having stored the extracts at 4 ◦C for
131.5 h and 129.5 h for dog and rat batches respectively.
All stability samples were processed and quantified against
freshly spiked CS and freshly spiked QC samples. The samples
were considered to be stable if the mean determined concen-
tration/nominal concentration was within 100 ± 15 % and the
coefficient of variation was  ≤15 % at each concentration level for
each stability experiment.
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2.8. Data processing and calculations
Data collection carried out during this study was performed
using Analyst Version 1.4.2 data handling software. Determina-
tion of the calibration parameters (slope, intercept and coefficient
of determination) and the calculation of mean, standard deviation
and accuracy data were performed using Thermo Fisher Scientific
WatsonTM Version 7.0 software. The nominal matrix concentra-
tions of CS and QC samples were entered to three significant figures.
Determined concentration data are determined to three significant
figures. For the CS and QC sample data, mean values were calcu-
lated from the unrounded determined concentration data and are
presented rounded to three significant figures. Accuracy data were
calculated from the rounded mean values and are presented to one
decimal place. Precision data were calculated from the unrounded
determined concentration data and peak area data and are pre-
sented rounded to one decimal place. Slopes and intercepts are
presented to four significant figures; coefficients of determination
are presented to four decimal places. Peak area ratios are presented
to six decimal places.
2.9. Pharmacokinetic study in dog
The PH46A capsules were prepared the day before the dosing by
weighing a suitable amount of PH46A into each capsule to achieve
a target dose level of 100 mg/kg. The capsule fill weights were
1077.4 mg,  1119.6 mg  and 990.4 mg  for Capsule 1 (001 M),  Capsule
2 (002 M)  and Capsule 3 (003 M),  respectively. Each capsule was
administered by placing it in the back of the throat of each animal
followed by swallowing and visual confirmation that the capsule
was swallowed. Following dosing, blood samples (1 mL)  were col-
lected from the jugular vein into tubes containing lithium heparin
as an anticoagulant at the following sampling times: pre-dose, 0.25,
0.75, 1, 2, 4, 6, 8, 12 and 24 h post-dose. Plasma was separated by
centrifugation (3000 rpm, 10 min  & 4 ◦C) prior to storage at −80 ◦C
until analysis. Individual PH46 plasma concentrations generated
were used to estimate pharmacokinetic parameters using WinNon-
Lin v4.1 pharmacokinetic software.
3. Results and discussion
3.1. Stability of PH46 and IS in stored stock solutions
Both PH46 and IS stock solutions were found to be stable for at
least 35 days at 4 ◦C, IS working solutions for at least 27 days at 4 ◦C
for, and PH46 stock solutions for at least 24 h at room temperature.
3.2. Specificity and linearity
The calibration data from both dog plasma (8 batches) and rat
plasma (7 batches) standards (over a range of 10−10000 ng/mL,
duplicate run at each concertation) were analysed. In all cases at
least 75 % of standards (and a minimum of 12 standards, includ-
ing at least one replicate at the LLOQ and ULOQ levels) used to
construct each calibration line met  the acceptance criterion of the
determined concentrations being within 100 ± 15 % of the nom-
inal concentrations (100 ± 20 % of the nominal concentration at
the LLOQ). Regression analysis of the peak area ratios of PH46:IS
against the concentration demonstrated good linearity for dog and
rat plasma over the range 10−10000 ng/m using a quadratic regres-
sion with a weighting factor of 1/x. For PH46 in dog plasma, the
mean values of the regression equation y = Ax2+Bx + C were A: -
0.000000007620, B: 0.0003271, C: 0.0002245 and R2 (coefficient
of determination): 0.9986 for Occasion 1; A: -0.000000004671, B:
0.0001919, C: 0.0002627 and R2: 0.9998 for Occasion 2 and A: -
0.000000004328, B: 0.0002098, C: 0.0005037 and R2: 0.9991 for
Occasion 3, where y: the peak-area ratio of PH46 to IS; x: the plasma
concertation of PH46. For PH46 in rat plasma, A: -0.000000004036,
B: 0.0001640, C: 0.0002521 and R2: 0.9977 for Occasion 1; A: -
0.000000005498, B: 0.0002251, C: 0.0007108 and R2: 0.9996 for
Occasion 2; A: -0.000000004418, B: 0.0002091, C: 0.0003914 and
R2: 0.9941 for Occasion 3. All determined concentrations for these
standards met  the acceptance criteria. The representative calibra-
tion curves from Occasion 2 are presented in Fig. 2.
The QC sample data for the supporting QC samples are presented
in Table 1, which met  the acceptance criteria of the determined con-
centrations being within 100 ± 15 % of the nominal concentration.
The assay specificity demonstrated there were no significant inter-
fering substances at the RTs of PH46 and IS. A peak at RT of IS was
observed in the PH46 chromatograms in samples containing IS due
to in-source breakdown of IS. This did not interfere with the PH46
peak as both peaks were well resolved. A peak was also observed
at RT of IS in samples containing only PH46, however, it was ≤5 %
of the IS response and was therefore within acceptable limits. Rep-
resentative chromatograms of dog plasma and rat plasma extracts
are shown in Figs. 3 and 4, respectively.
3.3. Assay recovery and matrix effects
For PH46 and IS in dog and rat plasma, the recoveries were con-
sistent (Table 2). For PH46 and IS in dog plasma, at PH46 of 25 ng/mL
the IS-normalised MFs  from all six sources were 1.094, 1.131, 1.149,
1.111, 1.198, 1.071 and the corresponding precision was 4.0 %. At
8000 ng/mL level, the MFs  were 1.248, 1.296, 1.312, 1.250, 1.382,
1.357 and the associate precision was 4.2 %. For PH46 and IS in
rat plasma, the MFs  at PH46 of 25 ng/mL were found to be 1.079,
1.028, 1.067, 1.054, 1.122, 1.029 and the precision was  3.3 %. At
8000 ng/mL level, the MFs  were 1.383, 1.262, 1.273, 1.263, 1.358,
1.261 and the precision was  4.3 %. These results demonstrated that
the matrix effects met  the acceptance criteria and no significant
matrix effect was present for PH46 and IS in both dog and rat plasma
by the current method.
3.4. Intra- and inter-assay accuracy and precision
The intra-batch accuracy and precision of the assay for PH46
in dog and rat plasma met the acceptance criteria for each of the
three batches at each of the four concentrations assessed (Table 3).
The inter-batch accuracy and precision also meet the acceptance
criteria on each occasion.
3.5. Assay carry-over and matrix dilution
No significant carry-over was  observed in the matrix blank and
solvent samples injected after a ULOQ sample for PH46 or IS in
both dog and rat plasma. The accuracy and precision for samples
prepared at 80000 ng/mL and diluted at 10- and 100-fold met  the
acceptance criteria for dog and rat plasma (Table 4). These results
showed that 10- and 100-fold dilutions of samples in control dog
or rat plasma had no effect on the accuracy and precision of the
method.
3.6. Stability experiments
Data from all the stability test for both dog and rat plasma are
shown in Table 5. All results met  the acceptance criteria and PH46A
and IS were stable in dog and rat plasma under current stability
test conditions. It was  concluded that PH46 and IS are stable in dog
and rat plasma extracts under the following conditions: at least
three freeze/thaw cycles at −20 ◦C, at least 24 h at ambient tem-
perature, at least 31 days and 30 days, respectively at −20 ◦C, and
143.5 h and 243.5 h respectively at the auto-sampler temperature
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of at 4 ◦C before being re-injected. The mean re-injection stabilities
of PH46 in extracts of dog and rat plasma stored at 4 ◦C for 131.5 h
and 129.5 h respectively, also met  the acceptance criteria.
3.7. Pharmacokinetic study
No adverse reactions to treatment were observed when dogs
001 M and 002 M were dosed orally, while animal 003 M produced
some frothy vomit at about 0.5 h post-dose and further yellow liq-
uid vomit at 1.5 h post-dose. The animals were fed ca 2 h post-dose
and after this period no further vomiting was observed. Except
for these incidences of emesis, there were no other reactions to
treatment.
The pharmacokinetic parameters are presented in Table 6
and the pharmacokinetic profiles are represented graphically in
Fig. 5. Maximal concentrations observed were variable within
the 3 animals, with the highest concentration (Cmax) observed
in animal 003 M (34900 ng/mL). Tmax was 2 h for animals 001 M
and 002 M,  however, Tmax for 003 M was 0.75 h. The half-life
of elimination (T1/2) was similar in animals 001 M and 002 M
(003 M not measurable) with a mean of 5.4 h. The mean AUC(0-t)
was 35000 ± 14700 ng.h/mL and mean AUC (0-inf) was  similar at
36900 ng.h/mL (n = 2).
4. Conclusion
A sensitive and specific analytical method was developed and
validated for the determination of PH46 in dog and rat plasma. A
range of testing, including linearity, accuracy, precision, specificity,
matrix effect, carry-over, dilution effect and stabilities, were estab-
lished for both matrices. The method meets EMA  validation criteria.
This method was  successfully applied to a pre-clinical pharmacoki-
netic study in dog.
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